secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001619856-23-000087
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CB-010 Phase 1 data: 94% ORR, 69% CR in r/r B-NHL; 44% CR ≥6 months; cash ~$292.5M
--------------------------------------------------------------------------------

- CB-010 achieved 94% ORR (15/16) and 69% CR (11/16) in r/r B-NHL patients in ANTLER Phase 1 dose escalation.
- 44% of patients (7/16) had CR at ≥6 months; longest CR maintained at 24 months.
- LBCL subgroup (N=10): 90% ORR, 70% CR, 50% CR at ≥6 months; longest CR 18 months.
- CB-010 generally well tolerated; no Grade 3+ CRS or GvHD; common Grade 3+ events: thrombocytopenia (69%), neutropenia (56%).
- Preliminary cash, cash equivalents & marketable securities ~$292.5M as of June 30, 2023; enrolling 2L LBCL in dose expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/0001619856-23-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/crbu-20230713.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer